At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 77 enrolled
Drug / intervention
Etanercept / Autoinjector Adrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-arm, Multicenter Study to Evaluate the Ability of Subjects With Rheumatoid Arthritis or Psoriatic Arthritis to Effectively Use a Reusable Electromechanical Autoinjector to Self-inject Etanercept
In Brief
A Phase 3 clinical trial evaluating Etanercept / Autoinjector A for Rheumatoid Arthritis and Psoriatic Arthritis. Completed, enrolled 77 participants across 13 sites.
Detailed Summary
The purpose of this study is to assess the ability of people with rheumatoid arthritis (RA) or psoriatic arthritis (PsA) to use an experimental autoinjector to self inject etanercept (Enbrel®).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis, Psoriatic Arthritis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartJun 2013
First PostedJul 2013
Primary CompletionDec 2013
Study CompletionDec 2013
TodayJul 2026
First PostedJul 17, 2013
Enrollment StartJun 11, 2013
Primary CompletionDec 18, 2013
Study CompletionDec 30, 2013
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 13.0 years ago
Interventions
Etanercept / Autoinjector Adrug
Autoinjector A, a hand-held, reusable electromechanical device, and a single-use, disposable cassette preassembled with an etanercept 50-mg liquid prefilled syringe (PFS).